Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...
Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.